-
1
-
-
65349104376
-
Tumors of the urinary system
-
In: Withrow SJ, Vail DM, eds., 4th ed. Philadelphia: WB Saunders Co
-
Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM, eds. Withrow & MacEwen's small animal clinical oncology. 4th ed. Philadelphia: WB Saunders Co, 2007;649-658.
-
(2007)
Withrow & MacEwen's small animal clinical oncology
, pp. 649-658
-
-
Knapp, D.W.1
-
3
-
-
0038079730
-
Management of transitional cell carcinoma
-
Henry CJ. Management of transitional cell carcinoma. Vet Clin North Am Small Anim Pract 2003;33:597-613.
-
(2003)
Vet Clin North Am Small Anim Pract
, vol.33
, pp. 597-613
-
-
Henry, C.J.1
-
4
-
-
0028477323
-
Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder
-
Knapp D, Richardson R, Chan T, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
-
(1994)
J Vet Intern Med
, vol.8
, pp. 273-278
-
-
Knapp, D.1
Richardson, R.2
Chan, T.3
-
5
-
-
0025428107
-
Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra: A retrospective study of 15 dogs
-
Moore AS, Cardona A, Shapiro W, et al. Cisplatin (cisdiamminedichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra: a retrospective study of 15 dogs. J Vet Intern Med 1990;4:148-152.
-
(1990)
J Vet Intern Med
, vol.4
, pp. 148-152
-
-
Moore, A.S.1
Cardona, A.2
Shapiro, W.3
-
6
-
-
0029818273
-
Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993)
-
Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc 1996;209:1588-1591.
-
(1996)
J Am Vet Med Assoc
, vol.209
, pp. 1588-1591
-
-
Chun, R.1
Knapp, D.W.2
Widmer, W.R.3
-
7
-
-
0033806440
-
Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer
-
Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221-226.
-
(2000)
Cancer Chemother Pharmacol
, vol.46
, pp. 221-226
-
-
Knapp, D.W.1
Glickman, N.W.2
Widmer, W.R.3
-
8
-
-
35548986259
-
Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder
-
Greene SN, Lucroy MD, Greenberg CB, et al. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2007;231:1056-1060.
-
(2007)
J Am Vet Med Assoc
, vol.231
, pp. 1056-1060
-
-
Greene, S.N.1
Lucroy, M.D.2
Greenberg, C.B.3
-
9
-
-
0031217671
-
Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder
-
Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
-
(1997)
J Vet Intern Med
, vol.11
, pp. 279-283
-
-
Chun, R.1
Knapp, D.W.2
Widmer, W.R.3
-
10
-
-
33746404198
-
Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder
-
Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
-
(2005)
Vet Comp Oncol
, vol.3
, pp. 73-80
-
-
Boria, P.A.1
Glickman, N.W.2
Schmidt, B.R.3
-
12
-
-
0037314711
-
Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma
-
Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 906-911
-
-
Henry, C.J.1
McCaw, D.L.2
Turnquist, S.E.3
-
13
-
-
0034277451
-
Prognostic factors in dogs with urinary bladder carcinoma
-
Rocha TA, Mauldin GN, Patnaik AK, et al. Prognostic factors in dogs with urinary bladder carcinoma. J Vet Intern Med 2000;14:486-490.
-
(2000)
J Vet Intern Med
, vol.14
, pp. 486-490
-
-
Rocha, T.A.1
Mauldin, G.N.2
Patnaik, A.K.3
-
14
-
-
0028221316
-
Comparison of three treatments for transitional cell carcinoma of the bladder in the dog
-
Helfand SC, Hamilton TA, Hungerford LL, et al. Comparison of three treatments for transitional cell carcinoma of the bladder in the dog. J Am Anim Hosp Assoc 1994;30:270-275.
-
(1994)
J Am Anim Hosp Assoc
, vol.30
, pp. 270-275
-
-
Helfand, S.C.1
Hamilton, T.A.2
Hungerford, L.L.3
-
15
-
-
0036125840
-
Future directions for gemcitabine in the treatment of genitourinary cancer
-
Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. Semin Oncol 2002;29:40-45.
-
(2002)
Semin Oncol
, vol.29
, pp. 40-45
-
-
Vogelzang, N.J.1
-
16
-
-
0036077791
-
Overview: Gemcitabine as single-agent therapy for advanced breast cancer
-
Tripathy D. Overview: gemcitabine as single-agent therapy for advanced breast cancer. Clin Breast Cancer 2002;3:8-11.
-
(2002)
Clin Breast Cancer
, vol.3
, pp. 8-11
-
-
Tripathy, D.1
-
18
-
-
0035082324
-
Phase I trial of gemictabine in patients with advanced pancreatic cancer
-
Okada S, Ueno H, Okusaka T, et al. Phase I trial of gemictabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 2001;31:7-12.
-
(2001)
Jpn J Clin Oncol
, vol.31
, pp. 7-12
-
-
Okada, S.1
Ueno, H.2
Okusaka, T.3
-
19
-
-
2942571455
-
Gemcitabine (Gemzar) in non-small cell lung cancer
-
Manegold C. Gemcitabine (Gemzar) in non-small cell lung cancer. Expert Rev Anticancer Ther 2004;4:345-360.
-
(2004)
Expert Rev Anticancer Ther
, vol.4
, pp. 345-360
-
-
Manegold, C.1
-
20
-
-
0036182570
-
The role of gemcitabine in the treatment of malignant mesothelioma
-
Kindler HL, van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol 2002;29:70-76.
-
(2002)
Semin Oncol
, vol.29
, pp. 70-76
-
-
Kindler, H.L.1
van Meerbeeck, J.P.2
-
21
-
-
0035424877
-
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation
-
Patel SRR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol 2001;19:3483-3489.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3483-3489
-
-
Patel, S.R.R.1
Gandhi, V.2
Jenkins, J.3
-
22
-
-
0141731181
-
Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma
-
Jones PD, de Lorimier LP, Kitchell BE, et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 2003;39:463-467.
-
(2003)
J Am Anim Hosp Assoc
, vol.39
, pp. 463-467
-
-
Jones, P.D.1
de Lorimier, L.P.2
Kitchell, B.E.3
-
23
-
-
7244221409
-
Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: A veterinary radiation therapy oncology group pilot study
-
LeBlanc AK, LaDue TA, Turrel JM, et al. Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study. Vet Radiol Ultrasound 2004;45:466-470.
-
(2004)
Vet Radiol Ultrasound
, vol.45
, pp. 466-470
-
-
LeBlanc, A.K.1
LaDue, T.A.2
Turrel, J.M.3
-
24
-
-
13544269471
-
Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies
-
Kosarek CE, Kisseberth WC, Gallant SL, et al. Clinical evaluation of gemcitabine in dogs with spontaneously occurring malignancies. J Vet Intern Med 2005;19:81-86.
-
(2005)
J Vet Intern Med
, vol.19
, pp. 81-86
-
-
Kosarek, C.E.1
Kisseberth, W.C.2
Gallant, S.L.3
-
25
-
-
61749098352
-
Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs
-
Marconato L, Lorenzo MR, Abramo F, et al. Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs. Vet Comp Oncol 2008;6:90-101.
-
(2008)
Vet Comp Oncol
, vol.6
, pp. 90-101
-
-
Marconato, L.1
Lorenzo, M.R.2
Abramo, F.3
-
26
-
-
0038186551
-
Antimetabolites
-
In: Perry MC, ed., Philadelphia: Lippincott Williams & Wilkins
-
Gutheil JC, Finucane DM. Antimetabolites. In: Perry MC, ed. The chemotherapy source book. Philadelphia: Lippincott Williams & Wilkins, 2001;219-220.
-
(2001)
The chemotherapy source book
, pp. 219-220
-
-
Gutheil, J.C.1
Finucane, D.M.2
-
27
-
-
0025978216
-
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
-
Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-498.
-
(1991)
J Clin Oncol
, vol.9
, pp. 491-498
-
-
Abbruzzese, J.L.1
Grunewald, R.2
Weeks, E.A.3
-
28
-
-
0029852961
-
Phase I studies with the novel nucleoside analog gemcitabine
-
Abbruzzese JL. Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol 1996;23:25-31.
-
(1996)
Semin Oncol
, vol.23
, pp. 25-31
-
-
Abbruzzese, J.L.1
-
29
-
-
0029973099
-
Gemcitabine: Once-weekly schedule active and better tolerated than twice-weekly schedule
-
Martin C, Lund B, Anderson H, et al. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs 1996;7:351-357.
-
(1996)
Anticancer Drugs
, vol.7
, pp. 351-357
-
-
Martin, C.1
Lund, B.2
Anderson, H.3
-
30
-
-
0029666336
-
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors
-
Veerman G, Ruiz van Haperen VW, Vermorken JB, et al. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 1996;38:335-342.
-
(1996)
Cancer Chemother Pharmacol
, vol.38
, pp. 335-342
-
-
Veerman, G.1
van Haperen Ruiz, V.W.2
Vermorken, J.B.3
-
31
-
-
0032834698
-
Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinical study in dogs
-
Cozzi PJ, Bajorin DF, Tong W, et al. Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs. Clin Cancer Res 1999;5:2629-2637.
-
(1999)
Clin Cancer Res
, vol.5
, pp. 2629-2637
-
-
Cozzi, P.J.1
Bajorin, D.F.2
Tong, W.3
-
34
-
-
0031090416
-
Sonographic evaluation of urinary bladder wall thickness in normal dogs
-
Geisse AL, Lowry JE, Schaeffer DJ, et al. Sonographic evaluation of urinary bladder wall thickness in normal dogs. Vet Radiol Ultrasound 1997;38:132-137.
-
(1997)
Vet Radiol Ultrasound
, vol.38
, pp. 132-137
-
-
Geisse, A.L.1
Lowry, J.E.2
Schaeffer, D.J.3
-
35
-
-
26844522727
-
Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0
-
Veterinary Cooperative Oncology Group
-
Veterinary Cooperative Oncology Group. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
-
(2004)
Vet Comp Oncol
, vol.2
, pp. 194-213
-
-
-
36
-
-
0030686593
-
Gemcitabine: A promising new agent in the treatment of urothelial cancer
-
Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of urothelial cancer. J Clin Onc 1997;15:3441-3445.
-
(1997)
J Clin Onc
, vol.15
, pp. 3441-3445
-
-
Moore, M.J.1
Tannock, I.F.2
Ernst, D.S.3
-
37
-
-
0019487795
-
Bladder cancer in pet dogs: A sentinel for environmental cancer?
-
Hayes HM Jr, Hoover R, Tarone RE. Bladder cancer in pet dogs: a sentinel for environmental cancer? Am J Epidemiol 1981;114:229-233.
-
(1981)
Am J Epidemiol
, vol.114
, pp. 229-233
-
-
Hayes Jr., H.M.1
Hoover, R.2
Tarone, R.E.3
-
38
-
-
17544402702
-
Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer
-
Mohammed SI, Craig BA, Mutsaers AJ, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003;2:183-188.
-
(2003)
Mol Cancer Ther
, vol.2
, pp. 183-188
-
-
Mohammed, S.I.1
Craig, B.A.2
Mutsaers, A.J.3
-
39
-
-
0033990160
-
Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer
-
Knapp DW, Glickman NW, DeNicola DB, et al. Naturally occurring canine transitional cell carcinoma of the urinary bladder. A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:47-49.
-
(2000)
Urol Oncol
, vol.5
, pp. 47-49
-
-
Knapp, D.W.1
Glickman, N.W.2
DeNicola, D.B.3
-
40
-
-
42249087303
-
Prediction of broad spectrum resistance of tumors towards anticancer drugs
-
Efferth T, Konkimalla VB, Wang YF, et al. Prediction of broad spectrum resistance of tumors towards anticancer drugs. Clin Cancer Res 2008;14:2405-2412.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2405-2412
-
-
Efferth, T.1
Konkimalla, V.B.2
Wang, Y.F.3
-
41
-
-
0141520276
-
Drug resistance and the microenvironment: Nature and nurture
-
Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003;6:169-172.
-
(2003)
Drug Resist Updat
, vol.6
, pp. 169-172
-
-
Morin, P.J.1
-
42
-
-
0028889426
-
Scheduledependent antitumor effect of gemcitabine in in vivo model system
-
Braakhuis BJ, Ruiz van Haperen VW, Boven E, et al. Scheduledependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995;22:42-46.
-
(1995)
Semin Oncol
, vol.22
, pp. 42-46
-
-
Braakhuis, B.J.1
van Haperen Ruiz, V.W.2
Boven, E.3
-
43
-
-
0027263596
-
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
-
Boven E, Schipper H, Erkelens CA, et al. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993;68:52-56.
-
(1993)
Br J Cancer
, vol.68
, pp. 52-56
-
-
Boven, E.1
Schipper, H.2
Erkelens, C.A.3
|